Samsung Biologics, South Korea’s leading contract development and manufacturing organization, has signed a CDMO deal with KAHR Medical, an Israeli cancer immunotherapy company, furthering its market expansion beyond America and Europe into the Middle East.

Samsung Biologics said on Wednesday it will provide end-to-end cell line development, clinical drug substance and drug product manufacturing services as well as IND filling support for KAHR`s drug candidate DSP502 under the agreement.

KAHR, an innovative leader in the fusion protein space, brags about its technology based on multi-functional immuno-recruitment proteins (MIRP) that bind cancer cells and T-cells to produce a synergistic effect to selectively target tumors.

KAHR’s lead product, DSP107, is a first in class CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses and activates effective immune responses, according to Yaron Pereg, Ph.D., Chief Executive Officer of KAHR Medical.

The latest achievement is the result of Samsung Biologics’ continued business expansion both at home and abroad. The company newly built an R&D center in San Francisco in October last year to ensure drug development services at a faster speed.

Samsung Biologics is currently building its fourth and largest biomanufacturing facility in Incheon, Korea. Upon completion in 2023, Samsung Biologics will hold 620,000 liters of biomanufacturing capacity in total, the world’s largest.

Samsung Biologics shares were unchanged from the previous session at 818,000 won ($736.27) in a muted response to the news in Thursday morning trading. The stock closed the day 0.73 percent higher at 824,000 won.

By Kim Si-gyun and Minu Kim

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]